FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

Video

Challenges for patients diagnosed with metastatic HER2+ breast cancer and recent FDA approved-therapies for the third-line setting are reviewed.

Related Videos
Video 5 - "AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes"
Rita Nanda, MD
Siddartha Yadav, MD, FACP
Nan Chen, MD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Ko Un “Clara” Park, MD
Erin Frances Cobain, MD
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Carlos Arteaga, MD
Related Content
Robert W. Mutter, MD

Data Continue to Illustrate Potential Role of Partial Breast Irradiation in Early-Stage Breast Cancer

April 24th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
FDA

FDA Approves Lumisight and Lumicell DVS for Residual Breast Cancer Detection

April 18th 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
Matt Coffey, PhD, president, chief executive officer, Oncolytics Biotech

FDA Receives Type C Meeting Request for Pelareorep in HR+/HER2– Metastatic Breast Cancer

April 12th 2024
Article
Karen Pinilla Alba, MD

Olaparib With Chemotherapy Does Not Elicit Improved Outcomes vs Chemotherapy Alone in BRCA Wild-Type TNBC

April 8th 2024
Article